🎉 M&A multiples are live!
Check it out!

Atossa Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Atossa Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Atossa Therapeutics Overview

About Atossa Therapeutics

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.


Founded

2009

HQ

United States of America
Employees

15

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$10.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Atossa Therapeutics Financials

Atossa Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Atossa Therapeutics achieved revenue of n/a and an EBITDA of -$27.6M.

Atossa Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Atossa Therapeutics valuation multiples based on analyst estimates

Atossa Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$31.4M -$27.6M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$27.0M -$30.1M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Atossa Therapeutics Stock Performance

As of April 15, 2025, Atossa Therapeutics's stock price is $1.

Atossa Therapeutics has current market cap of $82.0M, and EV of $10.9M.

See Atossa Therapeutics trading valuation data

Atossa Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$10.9M $82.0M XXX XXX XXX XXX $-0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Atossa Therapeutics Valuation Multiples

As of April 15, 2025, Atossa Therapeutics has market cap of $82.0M and EV of $10.9M.

Atossa Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Atossa Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Atossa Therapeutics and 10K+ public comps

Atossa Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $10.9M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.4x XXX XXX XXX
P/E -3.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Atossa Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Atossa Therapeutics Valuation Multiples

Atossa Therapeutics's NTM/LTM revenue growth is n/a

Atossa Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.8M for the same period.

Over next 12 months, Atossa Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Atossa Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Atossa Therapeutics and other 10K+ public comps

Atossa Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -12% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Atossa Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Atossa Therapeutics M&A and Investment Activity

Atossa Therapeutics acquired  XXX companies to date.

Last acquisition by Atossa Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Atossa Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Atossa Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Atossa Therapeutics

When was Atossa Therapeutics founded? Atossa Therapeutics was founded in 2009.
Where is Atossa Therapeutics headquartered? Atossa Therapeutics is headquartered in United States of America.
How many employees does Atossa Therapeutics have? As of today, Atossa Therapeutics has 15 employees.
Who is the CEO of Atossa Therapeutics? Atossa Therapeutics's CEO is Dr. Steven C. Quay, M.D.,PhD.
Is Atossa Therapeutics publicy listed? Yes, Atossa Therapeutics is a public company listed on NAS.
What is the stock symbol of Atossa Therapeutics? Atossa Therapeutics trades under ATOS ticker.
When did Atossa Therapeutics go public? Atossa Therapeutics went public in 2012.
Who are competitors of Atossa Therapeutics? Similar companies to Atossa Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Atossa Therapeutics? Atossa Therapeutics's current market cap is $82.0M
Is Atossa Therapeutics profitable? Yes, Atossa Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.